Screening Women for Functional Hypothalamic Amenorrhea (FHA)

Sponsor
Imperial College London (Other)
Overall Status
Recruiting
CT.gov ID
NCT05410886
Collaborator
University College, London (Other)
200
2
26
100
3.8

Study Details

Study Description

Brief Summary

What do the investigators know already? Many women suffer loss of periods (amenorrhoea). One of the most common causes of period loss is called 'functional hypothalamic amenorrhea' (FHA). FHA is difficult to diagnose and may be mistaken for other conditions causing period loss, such as polycystic ovarian syndrome (PCOS). This could cause delays in starting the correct treatment.

What is the justification for doing this study? Undiagnosed women with FHA are predisposed to complications related to low oestrogen levels, such as osteoporosis, bone fractures and infertility. The failure to accurately identify women with FHA and mislabel those women with FHA as having PCOS, may delay appropriate treatment. Treatment delay causes harm for affected women, including bone fractures and infertility.

What do the investigators propose? Improve the diagnosis of women with FHA by composing an assessment score, which could be used by women to improve the accuracy of diagnosing FHA. The investigators designed a questionnaire based on literature search, which can be used to identify women with FHA. A questionnaire-based study (on-line or in person) will be performed to identify risk of FHA, in women referred to hospital with period loss.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire

Detailed Description

A questionnaire was developed to be used by women with period loss to facilitate the diagnosis of women with FHA. The development of the questionnaire was based on systematic literature review and comments from a small patient involvement group, as per National Institute for Health and Care Research (NIHR) INVOLVE guidelines.

Participants will be recruited via distributing a patient information sheet, consent form and a questionnaire to all women referred with amenorrhea to the Endocrinology or Reproductive Medicine clinics at Imperial College Healthcare NHS Trust and/or participating NHS organisations. Completion of the consent form and questionnaire is entirely dependent on each potential participant's choice.

Every woman taking part can complete the questionnaire before or after her appointment. All questionnaires will be anonymised with a unique study code, and handed back to the NHS clinician.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
A Questionnaire-based Study to Improve the Diagnosis of Functional Hypothalamic Amenorrhea (FHA) in Women With Secondary Amenorrhea Attending Hospital
Actual Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Jul 31, 2024

Outcome Measures

Primary Outcome Measures

  1. Frequency of clinical features in women with Functional hypothalamic amenorrhea [3 years]

    Descriptive statistics will be applied to questionnaire responses looking at frequency of different clinical features in women with FHA and women with other diagnoses.

Other Outcome Measures

  1. Frequency of biochemical features in women with Functional hypothalamic amenorrhea [3 years]

    Descriptive statistics will be applied to standard medical investigation results looking at frequency of different biochemical features in women with FHA and women with other diagnoses.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 58 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Any woman 18-58 years of age

  • Secondary amenorrhea defined by either menstrual cycle interval persistently exceeding 45 days and/or those with period loss for 3 months or more

Exclusion Criteria:
  • Women who never had periods (primary amenorrhea).

Contacts and Locations

Locations

Site City State Country Postal Code
1 University College London Hospital NHS Trust London United Kingdom NW1 2BU
2 Imperial College Healthcare NHS Trust London United Kingdom W12 0HS

Sponsors and Collaborators

  • Imperial College London
  • University College, London

Investigators

  • Principal Investigator: Channa Jayasean, PhD, Imperial College London

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Imperial College London
ClinicalTrials.gov Identifier:
NCT05410886
Other Study ID Numbers:
  • 20HH6115
First Posted:
Jun 8, 2022
Last Update Posted:
Jun 10, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 10, 2022